Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 98
- Registration Number
- NCT01922349
- Locations
- 🇰🇷
1314.9.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT01917916
- Locations
- 🇰🇷
1293.8.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
🇯🇵1293.8.8101 Boehringer Ingelheim Investigational Site, Sumida-ku,Tokyo, Japan
Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 132
- Registration Number
- NCT01911780
- Locations
- 🇯🇵
1348.2.021 Boehringer Ingelheim Investigational Site, Chuo-ku,Tokyo, Japan
🇯🇵1348.2.019 Boehringer Ingelheim Investigational Site, Kita-ku, Osaka-shi, Osaka, Japan
🇯🇵1348.2.001 Boehringer Ingelheim Investigational Site, Kawasaki, Kanagawa, Japan
Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2015-08-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2
- Registration Number
- NCT01909778
- Locations
- 🇩🇪
1220.15.49006 Boehringer Ingelheim Investigational Site, Mainz, Germany
Nintedanib (BIBF 1120) in Mesothelioma
- Conditions
- Mesothelioma
- Interventions
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 545
- Registration Number
- NCT01907100
- Locations
- 🇦🇺
Northern Cancer Institute, St Leonards, New South Wales, Australia
🇺🇸Texas Oncology - McAllen, McAllen, Texas, United States
🇺🇸Cancer Care Northwest Centers, PS, Spokane Valley, Washington, United States
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT01907113
- Locations
- 🇩🇪
1245.12.1 Boehringer Ingelheim Investigational Site, Kiel, Germany
🇩🇪1245.12.2 Boehringer Ingelheim Investigational Site, Neuss, Germany
A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 21
- Registration Number
- NCT01905111
- Locations
- 🇨🇳
1300.15.88601 Boehringer Ingelheim Investigational Site, Taipei, Taiwan
🇯🇵1300.15.81001 Boehringer Ingelheim Investigational Site, Kashiwa-shi, Chiba, Japan
PMS of Trazenta on the Long-term Use as Add-on Therapy
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Trazenta
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4057
- Registration Number
- NCT01904383
A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 724
- Registration Number
- NCT01903356
Clinical Drug Trial in Healthy Male Subjects to Determine and Compare the Blood Concentrations of BI 144807 Following Administration as Oral Solution and Tablet Under Fasted and Fed Conditions
- Conditions
- Healthy
- Interventions
- Drug: BI 144807 intermediate doseDrug: BI 144807 high dose
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 31
- Registration Number
- NCT01897597
- Locations
- 🇩🇪
1313.9.1 Boehringer Ingelheim Investigational Site, Biberach, Germany